[Sequential chemotherapy with or without GM-CSF in acute myeloid leukemia (AML) in the advanced phase: current status of protocols EMA 86 and EMA 91].
Archimbaud
E
E
Service d'Hématologie, Hôpital Edouard Herriot, Lyon, France.
Leblond
V
V
Fenaux
P
P
Dombret
H
H
Cordonnier
C
C
Cony-Makoul
P
P
Dreyfus
F
F
Troussard
X
X
Auzanneau
G
G
Stoppa
A M
AM
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002453:Cell Cycle / Q000187:drug effects; D003609:Dactinomycin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged
D003609:Dactinomycin; D005047:Etoposide; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D008727:Methotrexate
Chimiothérapie séquentielle avec ou sans GM-CSF dans les leucémies aiguës myéloïdes (LAM) en phase avancée: état actuel des protocoles EMA 86 et EMA 91.